Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: How investors can best navigate the sector and market ahead?

November 4, 2024 6:13am

Vote and tune your earnings’ hearing

Earnings this week: Beam Therapeutics (BEAM), Ultragenyx Pharmaceuticals (RARE) 10/5 Tuesday; Ionis Pharmaceuticals (IONS), Lenz Therapeutics (LENZ) 11/6 Wednesday; Moderna (MRNA), Vericel (VCEL) and AxoGen (AXGN) 11/7 Thursday

There's always quite a more than a bit of uncertainty, so investors have to extract the signals from the noise

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Never leave an investor uninform

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Monday: The pre-open Dow futures are UP +0.14% or (+46 points), the S&P futures are UP +0.23% or (+13 points) and the Nasdaq futures are UP +0.22% or (+45 points) … futures won’t be specifically on target

Stock futures rose slightly on Monday, 11/4 as investors readied for a busy week that includes the U.S. presidential election and the Fed’s monetary policy meeting.
European markets were higher,
Asia-Pacific markets rose

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed UP +288.73 points or +0.69%, the S&P closed UP +23.35 points or +0.41% while the Nasdaq closed UP +144.77 points or +0.80%

Friday’s advance/decline line ended with a positive close at the close of 26 incliner, 7 decliners and 2 flats

The looming question remains how a Donald Trump or Kamala Harris victory will shape the market narrative for the rest of the year and beyond.

Economic Data Docket: Economic data: Factory orders, September (-0.5% expected, -0.2% prior), Durable goods orders, September (-0.8% expected, -0.8% prior)

Friday’s RegMed Investors (RMi) Closing bell and week and month’s end: “redeemed” … https://www.regmedinvestors.com/articles/13681

Q4/24: November 1 positive close

October: 8 positive and 15 negative closes

Q3/24:

September – 10 positive and 10 negative close

August – I neutral, 10 positive and 11 negative closes
July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

The BOTTOM LINE: If investors and funds are taking some risk off the table before the election, that can NOT ignore the depreciated share pricing of the sector.

My better half is “visiting” the hospital and I had to leave early this a.m., so, designated driver.

The cell and gene therapy sector started November with a positive close

October ended – with a negative close on Thursday, Wednesday and Tuesday after Monday’s positive close – ending the month of October

After a week of Monday through Friday as market headwinds drained share pricing growth.

Closed negative on last Friday, Thursday, Wednesday, Tuesday and Monday …

After the previous Friday climbed positive having dived on Thursday after positive closes on Wednesday, Tuesday and Monday pushed by a tailwind to a new high
After popping on the previous, previous Friday after diving Thursday, Wednesday after Tuesday and Monday negative closes
After the previous, previous, previous positive Friday, diving negative on the previous Thursday, Wednesday and Tuesday - October’s beginning.

The US presidential election is injecting some uncertainty into markets in the final fierce days of campaigning. Also, the closer we come to the “vote”; volatility could inject by the VIX (fear gauge) stimulating risk.

Keep overall exposure low and be ready to exit quickly.
As I have joked, “uncle algo and his electronic trading dwarfs” come to roost” until they fly away!

Welcome to my world of defining the “grey’ in our universe!

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.